Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 1 of 1
View Dan Albas Profile
Mr. Speaker, the parliamentary secretary specifically referenced the cost of drugs and what the government was doing to try to address that. I would just give this feedback for the member and for the government.
I was contacted last night by Theresa from my riding, who is the grandmother of nine-year-old Ruby. Ruby has cystic fibrosis. She has to do all sorts of things that kids her age never would have to contemplate, and it is very hard on her and her family.
Theresa specifically has said that Trikafta is not available. She says:
And now we have a government who is overhauling this already cumbersome system starting with the PMPRB...who has been mandated to decide the ceiling price that will be paid for prescription medicines. However, they have not been differentiating medicines for rare diseases, like cystic fibrosis, from more common diseases. They just want to get the medicines at the lowest price they can. We all want that, however, it isn't reasonable to think that rare diseases should be decided upon the same way others are as research development for rare diseases requires a will to proceed that is a far greater commitment of pharmaceutical firms.
The member has said that his government is trying to take action on the cost, but he is actually denying access for important medicines to help children like Ruby.
Could the member explain to Theresa why his government's plan is benefiting Canadians, particularly those who are wrestling with this horrible disease?
Result: 1 - 1 of 1

Export As: XML CSV RSS

For more data options, please see Open Data